Keith L Knutson Selected Research

Folate Receptor 1

1/2020	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients.
1/2020	Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
1/2018	Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.
7/2009	Functional folate receptor alpha is elevated in the blood of ovarian cancer patients.
3/2008	Folate receptor alpha as a tumor target in epithelial ovarian cancer.
9/2006	T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Keith L Knutson Research Topics

Disease

67	Neoplasms (Cancer) 04/2022 - 01/2002
28	Ovarian Neoplasms (Ovarian Cancer) 10/2020 - 06/2002
25	Breast Neoplasms (Breast Cancer) 11/2020 - 01/2002
5	Rheumatoid Arthritis 01/2020 - 06/2010
4	Infections 12/2018 - 10/2011
4	Carcinoma (Carcinomatosis) 04/2014 - 04/2006
3	Melanoma (Melanoma, Malignant) 01/2020 - 01/2002
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 08/2002
3	Disease Progression 07/2017 - 07/2006
3	Ovarian Epithelial Carcinoma 06/2014 - 03/2008
3	Inflammation (Inflammations) 10/2013 - 06/2009
3	Prostatic Neoplasms (Prostate Cancer) 06/2010 - 08/2002
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/2022 - 01/2022
2	COVID-19 11/2022 - 01/2022
2	Carcinogenesis 01/2018 - 02/2014
2	Glioblastoma (Glioblastoma Multiforme) 07/2003 - 08/2002
1	Cytopenia 04/2022
1	Breakthrough Infections 04/2022
1	Hematologic Neoplasms (Hematological Malignancy) 04/2022
1	Adenocarcinoma 01/2020
1	Experimental Melanoma 01/2020
1	Triple Negative Breast Neoplasms 01/2020
1	Adenocarcinoma of Lung 01/2019
1	Eosinophilia 01/2019
1	Lung Neoplasms (Lung Cancer) 01/2019
1	Lymphoma (Lymphomas) 11/2018
1	Breast Diseases (Breast Disease) 01/2018
1	Ascites 12/2017
1	Joint Diseases (Joint Disease) 01/2017
1	Pain (Aches) 01/2017
1	Osteoarthritis 01/2017

Drug/Important Bio-Agent (IBA)

25	VaccinesIBA 11/2022 - 01/2002
19	AntigensIBA 10/2020 - 08/2002
16	Peptides (Polypeptides)IBA 12/2018 - 04/2002
14	Proteins (Proteins, Gene)FDA Link 01/2020 - 04/2002
13	Neoplasm Antigens (Tumor Antigens)IBA 01/2018 - 06/2002
12	EpitopesIBA 01/2020 - 07/2002
11	CytokinesIBA 01/2020 - 04/2006
8	Biomarkers (Surrogate Marker)IBA 01/2019 - 07/2009
6	Folate Receptor 1IBA 01/2020 - 09/2006
6	Trastuzumab (Herceptin)FDA Link 01/2020 - 06/2010
6	AntibodiesIBA 01/2020 - 01/2002
6	Monoclonal AntibodiesIBA 01/2020 - 02/2004
5	Interleukin-10 (Interleukin 10)IBA 12/2017 - 04/2008
5	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 10/2011 - 05/2002
4	Messenger RNA (mRNA)IBA 11/2022 - 06/2014
4	Immune Checkpoint InhibitorsIBA 01/2020 - 11/2018
4	Interleukin-2 (IL2)IBA 01/2017 - 07/2006
4	HLA-DR Antigens (HLA-DR)IBA 02/2010 - 01/2006
4	EnzymesIBA 02/2010 - 05/2002
3	Pharmaceutical PreparationsIBA 01/2020 - 01/2002
3	RNA (Ribonucleic Acid)IBA 12/2018 - 01/2012
3	Protein Subunit VaccinesIBA 01/2018 - 01/2003
3	Interleukin-8 (Interleukin 8)IBA 01/2017 - 10/2011
3	Cancer VaccinesIBA 12/2015 - 01/2006
3	Transcription Factors (Transcription Factor)IBA 07/2014 - 06/2009
3	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2013 - 05/2002
3	ImmunosorbentsIBA 02/2010 - 05/2002
2	Estrogen ReceptorsIBA 11/2020 - 10/2006
2	DNA (Deoxyribonucleic Acid)IBA 12/2018 - 06/2010
2	LigandsIBA 01/2018 - 06/2011
2	ChemokinesIBA 01/2017 - 01/2012
2	Indicators and Reagents (Reagents)IBA 01/2017 - 04/2007
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2015 - 07/2011
2	Biological ProductsIBA 06/2014 - 06/2009
2	Folic Acid (Vitamin M)FDA LinkGeneric 07/2011 - 03/2008
2	invariant chain (Ii-Key)IBA 07/2011 - 01/2006
2	NF-kappa B (NF-kB)IBA 05/2011 - 06/2009
2	flt3 ligand protein (flt3 ligand)IBA 01/2003 - 04/2002
1	mRNA VaccinesIBA 04/2022
1	Cyclin-Dependent Kinase 4IBA 04/2022
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	Antineoplastic Agents (Antineoplastics)IBA 01/2021
1	durvalumabIBA 01/2020
1	Rheumatoid FactorIBA 01/2020
1	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 01/2020
1	margetuximabIBA 01/2020
1	pembrolizumabIBA 01/2020
1	B 31IBA 01/2019
1	NivolumabIBA 01/2019
1	Tumor Biomarkers (Tumor Markers)IBA 12/2018
1	Chimeric Antigen ReceptorsIBA 12/2018
1	micaIBA 01/2018
1	Estrogens (Estrogen)FDA Link 01/2017
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2017
1	Interleukin-16 (Interleukin 16)IBA 01/2017
1	Interferon-gamma (Interferon, gamma)IBA 01/2017
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017
1	Interleukin-7 (Interleukin 7)IBA 01/2017
1	human ERBB2 proteinIBA 01/2017
1	Interleukin-9 (Interleukin 9)IBA 01/2017
1	Interleukin-12 (IL 12)IBA 01/2017

Therapy/Procedure

31	Therapeutics 04/2022 - 07/2003
20	Immunotherapy 01/2020 - 01/2002
7	Drug Therapy (Chemotherapy) 04/2022 - 01/2004
1	Cytoreduction Surgical Procedures 01/2021
1	Hyperthermic Intraperitoneal Chemotherapy 01/2021
1	Intra-Articular Injections 01/2017
1	Knee Replacement Arthroplasty (Total Knee Replacement) 01/2017